Toxin in Medical Technology
Navigation Links
Toxin in Medical Technology
... protect against lethal anthrax infection by its toxin neutralization activity that allows the ... the anthrax Protective Antigen (PA) of the lethal toxin complex produced by the bacterium. Preclinical ... with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from ...
... the Condition & Enhance System and botulinum toxin type A injections (i.e., Botox(R)) experienced a ... are independent of the effects of botulinum toxin type A, therefore supporting the benefit of using ... in combination with: -- Botulinum toxin type A -- Intense pulsed light therapy ...
... in high density cultures, REP3123 inhibited toxin production at low concentrations (< 1 ug/mL) for ... as vancomycin and metronidazole did not reduce toxin production in these high density cultures even at ... recognize two disease-causing factors, toxin A ...
... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...
... in Europe have shown non-inferiority of NT-201 to one other botulinum toxin in the treatment of cervical dystonia," said Pappert. First Study ... double-blind studies in focal dystonia NT 201 and one other Botulinum toxin (BTXCo) have been used with a dose ratio of 1:1. The results demonstrate ...
... known as the anthrax Protective Antigen (PA) of the lethal and edema toxin complexes produced by the bacterium. Preclinical studies suggest that ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...
... therapeutic model, treatment with Valortim(R) is begun only after anthrax toxin is first detected in the circulation. This model may provide an ... a protein component known as the anthrax protective antigen of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is ...
... the common signs of aging -- including retinoids, alpha-hydroxy acids and other topical therapies, as well as chemical peels, lasers, botulinum toxin and skin fillers, to name a few. "The best advice I can offer my patients to improve their overall skin health is to wear sunscreen with a sun ...
... evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence. About Clostridium Difficile Infection CDI ...
... were analyzed. Results In the randomized, active-controlled, double-blind studies in focal dystonia NT-201 and one other Botulinum toxin (BoNT) have been used with a dose ratio of 1:1. The results demonstrate equivalent efficacy between the two products. Onset, waning, and duration of ...
... at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. ABthrax blocks the ...
... plays a major role in memory formation, leads to symptoms of PD-related dementia. To test this hypothesis, her group will administer a Parkinsonian toxin to preclinical models with lowered levels of acetylcholine, then measure their performance on a battery of cognitive tests. If the preclinical models ...
... high potency. For example, Dimebon treatment improved mitochondrial function and increased the number of surviving cells after treatment with a cell toxin known as ionomycin in a dose-dependent fashion. The effect of Dimebon to improve mitochondrial dysfunction has been confirmed in the independent ...
... Diagnostics Directive for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff assay targets the toxin B gene, found in toxigenic Clostriduim difficile strains. It is the only CDI diagnostic test that combines high assay sensitivity with a rapid ...
... of post-marketing clinical trials that confirm a clinical benefit of the biologic agent. About ONTAK ONTAK is a genetically engineered fusion toxin protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, ...
... antibody for the treatment of Alzheimer's disease. The antibody is intended to be used to promote clearance from the brain of beta amyloid, the toxin that leads to Alzheimer's disease. IN-N01 is Intellect's first drug candidate based on the technology invented by Dr. Daniel Chain, the Company's ...
... a long-term consequence of travelers' diarrhea, was three times greater in placebo than vaccine recipients. Iomai's vaccine uses an ETEC toxin delivered via a skin patch using the company's novel transcutaneous immunization (TCI) technology. ETEC causes illness through the toxins it ...
... other organisms that cause severe HAIs. These tests will identify the vanA and vanB genes associated with vancomycin-resistant enterococci and the toxin gene associated with Clostridium difficile. These rapid assays will further complement the Company's portfolio of HAI-related products. About BD ...
... are highly promising and clinically relevant." "Through a novel mechanism of action that inhibits growth and targets both sporulation and toxin production, REP3123 could be a future treatment option that tackles the main challenges associated with treating CDAD: high rates of relapse and new ...
... carries S. aureus, the predominant bacterial species associated with skin infections. PVL, the abbreviation for Panton-Valentine Leukocidin, is a toxin that -- when found in S. aureus -- "lyses," or breaks open, white blood cells and tissue cells which are needed to help the body fight the infection. ...
... and a member of the Company's Scientific Advisory Board. About Intellect's RECALL-VAX(TM) technology The key to inactivation of the beta-amyloid toxin by vaccination is to stimulate a strong antibody immune response that specifically targets the toxin. The proprietary RECALL-VAX(TM) technology ...
... study evaluating botulinum toxin type A (BTX-A, BOTOX(R)) as a treatment for ... London. "This study demonstrated that botulinum toxin type A may be a promising treatment option ... basline, 81 percent of patients in the botulinum toxin type A treatment group and 67 percent in ...
... of three non-toxic subunits of botulinum toxin that induced protection against the corresponding ... toxin) of three of the serotypes of botulinum toxin that cause almost all instances of human disease, ... These components lack the region of the toxin that are responsible for blocking ...
... demonstrating that mutated forms of botulinum toxin can be administered orally to induce protective immunity to natural toxin exposure. The claims in the granted European ... the use of certain non-toxic mutants of botulinum toxin that are capable of translocation from the gut to ...
... The paper, entitled "A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease" (JNCI, Vol.99, Issue 5 pp, 376-385) ... Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The ...
... component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...
... component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...
... ONTAK(R) (denileukin diftitox) ONTAK is a genetically engineered fusion toxin protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, resulting in a molecule that ...
... the Condition & Enhance System and botulinum toxin type A injections (i.e., Botox(R)) experienced a ... are independent of the effects of botulinum toxin type A, therefore supporting the benefit of using ... in combination with: -- Botulinum toxin type A -- Intense pulsed light therapy ...
... in high density cultures, REP3123 inhibited toxin production at low concentrations (< 1 ug/mL) for ... as vancomycin and metronidazole did not reduce toxin production in these high density cultures even at ... recognize two disease-causing factors, toxin A ...
... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...
... in Europe have shown non-inferiority of NT-201 to one other botulinum toxin in the treatment of cervical dystonia," said Pappert. First Study ... double-blind studies in focal dystonia NT 201 and one other Botulinum toxin (BTXCo) have been used with a dose ratio of 1:1. The results demonstrate ...
... known as the anthrax Protective Antigen (PA) of the lethal and edema toxin complexes produced by the bacterium. Preclinical studies suggest that ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
... humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen. (Logo: ... data." Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very ...DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
... protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in ...... therapeutic model, treatment with Valortim(R) is begun only after anthrax toxin is first detected in the circulation. This model may provide an ... a protein component known as the anthrax protective antigen of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is ...
The Leukemia & Lymphoma Society and Anjin Group Announce Multi-Year Collaborative Research Agreement
... provides for $2.9 million to accelerate the development of a fusion toxin protein for the treatment of acute myelogenous leukemia (AML). Continued ... and other diseases based on the fusion of a modified form of diphtheria toxin to proteins capable of selectively targeting cancerous and diseased cells. ...New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
... animals that survived in both studies were rapidly cleared of anthrax toxin and bacteria following intravenous administration of a single dose of ... are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes ...... the common signs of aging -- including retinoids, alpha-hydroxy acids and other topical therapies, as well as chemical peels, lasers, botulinum toxin and skin fillers, to name a few. "The best advice I can offer my patients to improve their overall skin health is to wear sunscreen with a sun ...
Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
... at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks ...... evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence. About Clostridium Difficile Infection CDI ...
... were analyzed. Results In the randomized, active-controlled, double-blind studies in focal dystonia NT-201 and one other Botulinum toxin (BoNT) have been used with a dose ratio of 1:1. The results demonstrate equivalent efficacy between the two products. Onset, waning, and duration of ...
Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
... from the New Jersey Commission on Science and Technology and the Foundation of UMDNJ Annual Program Committee Awards. Leukotoxin is a bacterial toxin that targets while blood cells. In laboratory studies, malignant white blood cells have been determined to be more sensitive to Leukotoxin than ...... at the cellular level. After protective antigen and the anthrax toxins are produced by the bacteria, protective antigen binds to the anthrax toxin receptor on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. ABthrax blocks the ...
... plays a major role in memory formation, leads to symptoms of PD-related dementia. To test this hypothesis, her group will administer a Parkinsonian toxin to preclinical models with lowered levels of acetylcholine, then measure their performance on a battery of cognitive tests. If the preclinical models ...
... high potency. For example, Dimebon treatment improved mitochondrial function and increased the number of surviving cells after treatment with a cell toxin known as ionomycin in a dose-dependent fashion. The effect of Dimebon to improve mitochondrial dysfunction has been confirmed in the independent ...
... Diagnostics Directive for the identification of toxigenic Clostridium difficile directly from stool specimens, the BD GeneOhm Cdiff assay targets the toxin B gene, found in toxigenic Clostriduim difficile strains. It is the only CDI diagnostic test that combines high assay sensitivity with a rapid ...
... of post-marketing clinical trials that confirm a clinical benefit of the biologic agent. About ONTAK ONTAK is a genetically engineered fusion toxin protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, ...
... antibody for the treatment of Alzheimer's disease. The antibody is intended to be used to promote clearance from the brain of beta amyloid, the toxin that leads to Alzheimer's disease. IN-N01 is Intellect's first drug candidate based on the technology invented by Dr. Daniel Chain, the Company's ...
... a long-term consequence of travelers' diarrhea, was three times greater in placebo than vaccine recipients. Iomai's vaccine uses an ETEC toxin delivered via a skin patch using the company's novel transcutaneous immunization (TCI) technology. ETEC causes illness through the toxins it ...
Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
... in the United-States, Epiduo(R), an innovative combination product for the acne treatment in Europe and Argentina, and Dysport(R), a botulinum toxin type A product for use in aesthetic medicine and dermatological indications in Brazil and Argentina. The company's website is ...Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
... improvement or ability to tolerate pharmacotherapy, more aggressive measures may be utilized, including the investigational injection of botulism toxin (e.g., Botox, Allergan), neurostimulation (e.g., InterStim, Medtronic) or surgical intervention. Surgery in this population is generally reserved for ...... other organisms that cause severe HAIs. These tests will identify the vanA and vanB genes associated with vancomycin-resistant enterococci and the toxin gene associated with Clostridium difficile. These rapid assays will further complement the Company's portfolio of HAI-related products. About BD ...
Replidyne Provides Strategic Update
... methionyl tRNA synthetase that blocks the organism from synthesizing proteins. In preclinical studies, REP3123 has been shown to inhibit growth, toxin production and spore-forming in C. difficile bacteria while leaving normal gut flora unharmed. Replidyne intends to file an investigation new drug ...CuraGen Announces Top-Line Phase II Results on Velafermin
... Poster Session A: Clinical Trials CR011-vcMMAE Title: A Phase I and Pharmacokinetic Study of CR011-vcMMAE, an Antibody toxin Conjugate Drug, in Patients with Unresectable Stage III /IV Melanoma Date: Wednesday, October 24, 2007 Poster Board: ...... are highly promising and clinically relevant." "Through a novel mechanism of action that inhibits growth and targets both sporulation and toxin production, REP3123 could be a future treatment option that tackles the main challenges associated with treating CDAD: high rates of relapse and new ...
... carries S. aureus, the predominant bacterial species associated with skin infections. PVL, the abbreviation for Panton-Valentine Leukocidin, is a toxin that -- when found in S. aureus -- "lyses," or breaks open, white blood cells and tissue cells which are needed to help the body fight the infection. ...
... and a member of the Company's Scientific Advisory Board. About Intellect's RECALL-VAX(TM) technology The key to inactivation of the beta-amyloid toxin by vaccination is to stimulate a strong antibody immune response that specifically targets the toxin. The proprietary RECALL-VAX(TM) technology ...
... study evaluating botulinum toxin type A (BTX-A, BOTOX(R)) as a treatment for ... London. "This study demonstrated that botulinum toxin type A may be a promising treatment option ... basline, 81 percent of patients in the botulinum toxin type A treatment group and 67 percent in ...
Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
... forced dose escalation study of Botulinum toxin Type B Injectable Solution (Myobloc(R)) recently ... 12,500 Units, and 15,000 Units of Botulinum toxin Type B in patients with cervical dystonia (CD). ... "The recommended initial dose of Type B toxin for patients with a prior history of tolerating ...... of three non-toxic subunits of botulinum toxin that induced protection against the corresponding ... toxin) of three of the serotypes of botulinum toxin that cause almost all instances of human disease, ... These components lack the region of the toxin that are responsible for blocking ...
... demonstrating that mutated forms of botulinum toxin can be administered orally to induce protective immunity to natural toxin exposure. The claims in the granted European ... the use of certain non-toxic mutants of botulinum toxin that are capable of translocation from the gut to ...
... The paper, entitled "A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease" (JNCI, Vol.99, Issue 5 pp, 376-385) ... Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The ...
... component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...
... component known as the anthrax protective antigen (PA) of the lethal toxin complex produced by the bacterium. The anthrax protective antigen is ... of antibody after a month, with a similar potency for neutralizing anthrax toxin in vitro as was seen with serum obtained from subjects who had been ...
... ONTAK(R) (denileukin diftitox) ONTAK is a genetically engineered fusion toxin protein consisting of the amino acid sequences for the enzymatically-active portion of diphtheria toxin fused to the sequence of human interleukin-2, resulting in a molecule that ...
Other ContentspigmentosumxerodermadiffractiondiffractiondiffractionplugplugplugplugplugyolkyolkyolkfingerfingerfingerfingerfingerfingerfingerzinczinczinczinczinczincOther TagsAutoAutoAutoAutoAutoAutoAutoAutoLDLLDLLDLDiluentDiluentWashWashWashWashBeanBeanBeanOther Tagsterm 2term 3term 4term 5term 6term 7term 8term 9term 10long 2long 3long 4long 5long 6long 7long 8long 9long 10offers 2offers 3offers 4offers 5offers 6offers 7offers 8offers 9offers 10procedure 2procedure 3procedure 4procedure 5procedure 6procedure 7procedure 8procedure 9procedure 10invasive 2invasive 3invasive 4invasive 5invasive 6invasive 7invasive 8invasive 9invasive 10including 2including 3including 4including 5including 6including 7including 8including 9including 10surveys 2surveys 3
(Date:11/24/2009)...ands of years it has been prescribed by traditiona...rom headaches and stomach pain to fever and flu. ,... University have been able to scientifically prove... otherwise known as Brazilian mint. , Testing th...ed by researcher Graciela Rocha was able to show t...
(Date:11/24/2009)...s have crystallised a protein that may help gut ba...tein could be used by probiotic producers to ident...to people. , "Probiotics need to interact with ce...d if they attach to surfaces in the gut they are m...eir activity," says Dr Nathalie Juge from the Inst...
(Date:11/24/2009)...and the American College of Medical Toxicology (AC... publication of the Journal of Medical Toxicology...ng in March 2010. It was previously published by ...urnal of Medical Toxicology , an international, pe... science and practice of medical toxicology. The ...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 2Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3American Joint Replacement Registry Announced 52562 1American Joint Replacement Registry Announced 52562 2(Date:11/27/2009)...ov. 27 /PRNewswire/ - Uploadable USB pedometers ma... wellness. A combination of advanced accelerometer...ng a long term concern over the accuracy of self-r...e and reward improved participation in a fitness p...e first wellness suppliers to integrate this techn...
(Date:11/27/2009)...ewswire-USNewswire/--Consideredahighlyriskyandcont...transplantationisnowalife-savingmainstreamoperatio...heWinspearOperaHouseinDallasonNov.11.Leaderscameto...he25thanniversaryofBaylorRegionalTransplantInstitu...heUnitedStates. ,, Itwas25yearsagothatBaylorHea...
(Date:11/27/2009)...Y., Nov. 27 Preventing ...and fortunately every year, new vaccines are being... vaccines boost immunity for the same period of ti...s, needed to keep immunity strong? ,, In this...merican Academy of Pediatrics, Michael Pichichero ...
(Date:11/27/2009)..., Israel, Nov. 27 Shamir... ), a leading provider of innovative products and ...d today that its board of directors had declared a...S$ 10 million (approximately NIS 37.62 million bas... exchange), or approximately US$ 0.609 (approximat...
(Date:11/27/2009)...low-emission vehicles may reduce future disease bu...7 (HealthDay News) -- Encouraging city dwellers to...r much greater public health benefits than increas... have found. , The study compared the projected...transport scenarios for London, England, and Delhi...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2[0] New USB technology adds accountability and convenience to wellness programs[0] Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary[0] Why Some Vaccines May Require A Booster[0] Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend[0] More Foot Power, Less Car Pollution Best for Health
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |